UNSPSC 51383308: Robenacoxib

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13F4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z588009C7C. The term ROBENACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53). Most nations schedule robenacoxib under HS 29224995 and SITC 51465. As of Q4 2014, ROBENACOXIB remains the US FDA Preferred Term for this commodity. Robenacoxib bears US NLM identifiers UMLS ID C2825257 and NCI Concept Code C80565.

SMILES: CCC1=CC(=C(C=C1)NC2=C(C(=CC(=C2F)F)F)F)CC(=O)O.

UNSPSC 51383308 Robenacoxib, a Commodity code, shows minimal recent activity aligned with its pharmaceutical scope. The single recent state-local opportunity posted under this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—does not match the code's nominal designation for robenacoxib, a veterinary anti-inflammatory medication. The procurement itself targets community health naloxone supply and safe drug disposal systems rather than the animal pharmaceutical robenacoxib implies, indicating either a misclassification in the county's tagging system or a data-entry error. State and local buyers do procure pharmaceuticals and medical supplies through UNSPSC taxonomy, but this particular code shows no verifiable recent opportunities in its intended scope.

Seminole County, Florida posted the only recent opportunity on June 30, 2026, with a response deadline of July 26, 2023 (note: the date discrepancy suggests a data quality issue in the source). The solicitation sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB included a two-year initial term with a one-year renewal option, E-Verify and drug-free workplace compliance requirements, and potential FEMA funding with associated federal environmental compliance obligations. Given the code's actual pharmaceutical content and the absence of recent opportunities genuinely aligned with robenacoxib procurement, this code warrants close monitoring but shows no actionable current activity for firms in veterinary pharmaceutical supply.